Asper Clinical Research Institute

Winnipeg, Manitoba R2H 2A6

0 studies enrolling now · 1 studies all time

What they study most

Heterozygous Familial Hypercholesterolemia

Studies at this site

• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia — Completed